Krystal Biotech: New promising results published (Phase 1/2 trial) in Nature Medicine
Gene therapy gel (formerly called B-VEC) from Krystal Biotech, safely and effectively improved wound healing in children and adults with recessive dystrophic epidermolysis bullosa (RDEB), according to phase 1/2 clinical trial data.
Importantly, treated wounds remained closed for at least three months and up to eight months.
These results, along with positive preclinical data obtained prior to the trial, were detailed in the study, "In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial", published in the journal Nature Medicine.
"The wounds heal quickly, but more importantly, they stay closed," Dr Peter Marinkovich, lead author of the study and head of the blistering clinic at Stanford University School of Medicine, where the study was conducted, said in a university press release.